Application of compound composition of eplerenone and isosorbide in preparation of product for treating or preventing motion sickness

The compound composition of eplerenone and isosorbide solves the problem of major side effects of existing anti-sports disease drugs by using half the amount of eplerenone and isosorbide, and realizes the occurrence of exercise disease before or when it occurs. Effective prevention and treatment, and can be used intravenously when nausea and vomiting.

CN118924770AInactive Publication Date: 2024-11-12NANTONG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411048998.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-01
Publication Date
2024-11-12
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing anti-sports disease drugs have great side effects and their effects are weakened after the onset of exercise diseases, and there is a lack of efficient preventive and therapeutic drugs without central inhibitory side effects.

Method used

Compound compositions of eplerenone and isosorbide are used as infusion or oral dosage forms to produce anti-motion disease effects before or during exercise disease. By using half the amount of eplerenone and isosorbide , reduce or reduce side effects.

Benefits of technology

It achieves effective prevention and treatment before or when exercise disease occurs, reduces the side effects of the original drugs, and can be used intravenously during nausea and vomiting.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924770A_ABST
    Figure CN118924770A_ABST
Patent Text Reader

Abstract

The invention provides an application of a compound composition of eplerenone and isosorbide in preparation of a product for treating or preventing motion sickness, relates to preparation of biological medicines, and is technically characterized in that the application of the compound composition of eplerenone and isosorbide in preparation of the product for treating or preventing motion sickness. The product has an anti-motion sickness effect when or before motion sickness occurs. The compound composition of eplerenone and isosorbide can avoid the problems of central side effect of the existing anti-motion sickness medicine and poor treatment effect of the existing medicine after motion sickness. Therefore, the compound composition of eplerenone and isosorbide can relieve the motion sickness, relieve the pain of patients, and ensure that people can travel pleasantly and comfortably and work smoothly in special environments.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application belongs to the field of biopharmaceutical technology, and specifically relates to the use of a compound composition of eplerenone and isosorbide in the preparation of a product for treating or preventing motion sickness. Background Art

[0002] When people are riding in vehicles, ships, airplanes, or doing navigation, aviation, aerospace, or in virtual reality, they are exposed to abnormal vestibular stimulation or / and abnormal visual stimulation. Many people will experience motion sickness (or motion sickness), which is mainly manifested by pale complexion, cold sweat, salivation, indifference, abdominal discomfort, dizziness, nausea, vomiting, etc. It is also called motion sickness, seasickness, navigation motion sickness, airsickness, aviation motion sickness, aerospace motion sickness, simulator sickness, etc. Literature shows that almost all crew members will get seasick when sailing in bad sea conditions; during aerospace operations, the incidence of motion sickness can still reach 60%-80% despite simulated training on the ground. Although motion sickness will gradually ease after leaving the sports environment, it obviously affects people's normal travel and operations in special environments such as aviation, aerospace, and navigation. At present, the detailed pathogenesis of motion sickness is still not very clear, and there is still a lack of efficient and side-effect-free drugs for prevention and treatment. Existing anti-motion sickness drugs include antihistamines, anticholinergics, sympathomimetics, calcium antagonists, gastrokinetics, traditional Chinese medicines such as salvia miltiorrhiza, gastrodia elata, ginger or compound preparations, etc.

[0003] At present, the most commonly used drug for preventing and treating motion sickness is the antihistamine dimenhydrinate, and the most effective single drug is the anticholinergic scopolamine, but the effective sites of these drugs are not very clear, and the side effects are also large, especially the side effects such as central inhibition, blurred vision, memory impairment, etc., which affect people's operations under various special environmental conditions such as navigation, aviation, and aerospace. In addition, these drugs are mostly used before taking a vehicle. As a preventive drug for motion sickness, they are effective, but if motion sickness has already occurred, their effects are significantly weakened. Therefore, it is necessary to research and develop new anti-motion sickness drugs with good effects, strong specificity, no obvious toxic and side effects, especially no central inhibition side effects, especially drugs with obvious therapeutic effects. Summary of the invention

[0004] The present application provides the use of a compound composition of eplerenone and isosorbide in the preparation of a product for treating or preventing motion sickness, so as to solve the above-mentioned technical problems.

[0005] In order to solve the above technical problems, a technical solution adopted in this application is:

[0006] Application of a compound composition of eplerenone and isosorbide in preparing a product for treating or preventing motion sickness.

[0007] Preferably, the compound composition comprises eplerenone and isosorbide.

[0008] Preferably, the product is used when motion sickness occurs or before it occurs to produce an anti-motion sickness effect.

[0009] Preferably, the product is in the form of an infusion or an oral dosage form.

[0010] A method for verifying that a compound composition of eplerenone and isosorbide inhibits motion sickness symptoms comprises the following steps:

[0011] S1. Obtain the drinking amount and swimming trajectory of 0.15% sodium saccharin solution of normal guinea pigs;

[0012] S2. Obtain the drinking amount of 0.15% saccharin sodium solution of guinea pigs with motion sickness, the drinking amount of 0.15% saccharin sodium solution of guinea pigs gavaged with half the normal dose of eplerenone, the drinking amount of 0.15% saccharin sodium solution of guinea pigs gavaged with half the normal dose of 70% isosorbide, and the drinking amount of 0.15% saccharin sodium solution of guinea pigs gavaged with a compound composition of half the normal dose of eplerenone and half the normal dose of 70% isosorbide, and compare it with the drinking amount of 0.15% saccharin sodium solution of normal guinea pigs;

[0013] S3. Obtain the swimming trajectories of guinea pigs with motion sickness, the swimming trajectories of guinea pigs gavaged with half the normal dose of eplerenone, the swimming trajectories of guinea pigs gavaged with half the normal dose of 70% isosorbide, and the swimming trajectories of guinea pigs gavaged with a combination of half the normal dose of eplerenone and half the normal dose of 70% isosorbide, and compare them with the swimming trajectories of normal guinea pigs.

[0014] The beneficial effects of the present application are: the isosorbide in the present application has no specific target except for the dehydrating effect, and it is found that it has a certain preventive and therapeutic effect on motion sickness. At the same time, the present application finds that eplerenone, a second-generation mineralocorticoid receptor antagonist, also has a certain preventive and therapeutic effect on motion sickness. The present application uses half of the original effective dose, exerts a synergistic effect from different links, achieves a good effect of preventing and treating motion sickness, and reduces or alleviates the side effects of the original drugs. It can be used when motion sickness has already occurred, and can also be used before taking a means of transportation. When motion sickness occurs, the patient will experience nausea and vomiting, which affects the administration, and can be used through the intravenous route. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 is a graph showing changes in the amount of saccharin sodium solution consumed by guinea pigs in each experimental group of Example 1;

[0016] Figure 2 It is a statistical diagram of the curvature of the swimming trajectory of guinea pigs in each experimental group of Example 2. DETAILED DESCRIPTION

[0017] In order to make the objectives, technical solutions and advantages of the present invention more clear, the present invention is further described in detail below in conjunction with specific embodiments.

[0018] In the following description, many specific details are set forth to facilitate a full understanding of the present invention. However, the present invention may also be implemented in other ways than those described herein. Therefore, the present invention is not limited to the specific embodiments of the following disclosure.

[0019] The use of a compound composition of eplerenone and isosorbide in the preparation of a product for treating or preventing motion sickness. The product comprises a compound composition of eplerenone and isosorbide. The product produces an anti-motion sickness effect when used when or before motion sickness occurs. The product is in the form of an infusion or an oral dosage form.

[0020] The present application also provides a method for verifying that a compound composition of eplerenone and isosorbide inhibits motion sickness manifestations, comprising the following steps:

[0021] S1. Obtain the drinking amount and swimming trajectory of 0.15% sodium saccharin solution of normal guinea pigs;

[0022] S2. Obtain the drinking amount of 0.15% saccharin sodium solution of guinea pigs with motion sickness, the drinking amount of 0.15% saccharin sodium solution of guinea pigs gavaged with half the normal dose of eplerenone, the drinking amount of 0.15% saccharin sodium solution of guinea pigs gavaged with half the normal dose of 70% isosorbide, and the drinking amount of 0.15% saccharin sodium solution of guinea pigs gavaged with a compound composition of half the normal dose of eplerenone and half the normal dose of 70% isosorbide, and compare it with the drinking amount of 0.15% saccharin sodium solution of normal guinea pigs;

[0023] S3. Obtain the swimming trajectories of guinea pigs with motion sickness, the swimming trajectories of guinea pigs gavaged with half the normal dose of eplerenone, the swimming trajectories of guinea pigs gavaged with half the normal dose of 70% isosorbide, and the swimming trajectories of guinea pigs gavaged with a combination of half the normal dose of eplerenone and half the normal dose of 70% isosorbide, and compare them with the swimming trajectories of normal guinea pigs.

[0024] Studies have shown that rotational stimulation can effectively induce motion sickness in guinea pigs. Guinea pigs are a type of rodent. Since rodents do not have a vomiting reflex, they will not vomit, but they will show conditioned taste aversion and abnormal movement trajectories. The former is used to reflect human nausea and vomiting, and the latter is used to reflect human vertigo, which is an abnormal vestibular function. Therefore, we used rotational stimulation to induce motion sickness in guinea pigs, and used the guinea pigs' aversion to 0.15% sodium saccharin solution and abnormal swimming trajectories as indicators, and observed that the compound composition of eplerenone and isosorbide had a significant anti-motion sickness effect.

[0025] Example 1: Inhibitory effect of the compound composition of eplerenone and isosorbide on conditioned taste aversion behavior induced by rotational stimulation in guinea pigs

[0026] The eplerenone used in the experiment was purchased from Beijing Huawei Ruike Chemical Co., Ltd. and isosorbide was purchased from Rhawn Reagent Co., Ltd. Saccharin sodium was produced by Tianjin Northern Food Co., Ltd. The experimental animals were ordinary guinea pigs, female, 2-3 months old, weighing 280-350g, purchased from the Experimental Animal Center of Nantong University. Guinea pigs were kept in plastic cages, free to move and eat, and fed with appropriate amounts of cabbage to supplement vitamins. The breeding environment was a 12h-12h light-dark cycle per day, a temperature of 22±2℃, and a relative humidity of 40%-70%, and the adaptive breeding was carried out for 3 days.

[0027] Control group (Con.): Guinea pigs were gavaged with an equal amount of physiological saline containing 0.5% sodium carboxymethyl cellulose, and the intake of 0.15% sodium saccharin solution by normal guinea pigs was continuously monitored two days before and two days after gavage, and the change in intake was calculated, i.e.: the percentage change in the intake of sodium saccharin solution = (the average intake of sodium saccharin solution 2 days after administration - the average intake 2 days before administration) / the average intake 2 days before administration.

[0028] Rotational stimulation group (Veh.): Guinea pigs were stimulated with a dual-axis compound rotational pattern to induce motion sickness, which was determined by measuring the reduction in the guinea pigs' intake of a pre-familiar 0.15% sodium saccharin solution (i.e., conditioned taste aversion behavior). The guinea pigs were placed in a rotational stimulation device and slowly rotated clockwise around the vertical axis at a constant speed (30° / s), and then rotated around the horizontal axis at a variable speed, first at 16° / s 2 The angular acceleration accelerates, rotating clockwise, and immediately after the angular velocity reaches the maximum value of 120° / s, it decreases to -48° / s 2 The angular acceleration of the guinea pig was decelerated until it stopped, with 10 seconds as one cycle. Subsequently, the guinea pig was rotated in the same counterclockwise direction for 10 seconds, and the stimulation was repeated for 120 minutes to induce motion sickness in the guinea pig. Immediately after the stimulation, the guinea pig was gavaged with an equal amount of saline containing 0.5% sodium carboxymethyl cellulose. The intake of 0.15% sodium saccharin solution by the guinea pig was continuously monitored two days before and after the rotation stimulation, and the changes in intake were calculated.

[0029] Eplerenone gavage group (Epl.): first perform rotation stimulation under the same conditions as above, and immediately after the stimulation, gavage the guinea pigs with half the normal dose of eplerenone (12.5 mg / kg). Continuously monitor the intake of 0.15% saccharin sodium solution by normal guinea pigs two days before and two days after gavage of eplerenone, calculate the changes in intake, and observe the effects of simple eplerenone.

[0030] Isosorbide gavage group (Iso.): first perform rotation stimulation under the same conditions as above, and immediately after the stimulation, gavage guinea pigs with half the normal dose of 70% isosorbide (0.7g / kg). Continuously monitor the intake of 0.15% saccharin sodium solution by normal guinea pigs two days before and two days after gavage of isosorbide, calculate the changes in intake, and observe the effect of simple isosorbide.

[0031] Group of compound composition gavage after rotation stimulation (Epl.+Iso.): First, the above-mentioned rotation stimulation was carried out under the same conditions. Immediately after the stimulation, the guinea pigs were gavaged with a compound composition of half the normal dose of eplerenone (12.5 mg / kg) and half the normal dose of 70% isosorbide (0.7 g / kg). The changes in the intake of 0.15% saccharin sodium solution were observed and compared with the performance of the control group and the rotation stimulation group to determine the anti-motion sickness effect of the compound composition of eplerenone and isosorbide. The results of each experimental group were statistically processed by variance analysis, and the Duncan test was used for pairwise comparison.

[0032] See also Figure 1 Compared with the control group (Con.), the amount of saccharin sodium solution consumed by the guinea pigs in the rotation stimulation group (Veh.) after rotation was significantly less than that before rotation (P<0.01), indicating that the rotation stimulation caused the guinea pigs to develop a conditioned taste aversion behavior of drinking saccharin sodium solution, that is, motion sickness. The guinea pigs that were immediately gavaged with eplerenone (12.5mg / kg, Epl.) or isosorbide (0.7g / kg, Iso.) alone after rotation stimulation showed a decrease in the amount of saccharin sodium solution consumed after rotation, but there was no significant difference compared with the simple rotation stimulation group (Veh.) (P>0.05), indicating that the inhibitory effect of half the normal dose of eplerenone or isosorbide on motion sickness was not obvious. However, after the combined use of half-dose of eplerenone and isosorbide, the conditioned taste aversion behavior of guinea pigs induced by rotational stimulation was significantly inhibited (P<0.01, Epl.+Iso.), and the drinking amount of sodium saccharin solution returned to the level of the control group, indicating that the combination of eplerenone and isosorbide has a significant anti-motion sickness effect.

[0033] Example 2: Inhibitory effect of the compound composition of eplerenone and isosorbide on the vestibular dysfunction induced by rotational stimulation in guinea pigs

[0034] Control group (Con.): Adaptive swimming training was performed on guinea pigs using the Morris water maze apparatus at a fixed time every day. Warm water was placed in a pool with a diameter of 1.8 m to ensure that the guinea pigs could not stand in the water. The platform in the water was removed and the guinea pig was gently placed in the center of the pool facing the pool wall. The swimming path of the guinea pig from the center to the pool wall was filmed with a camera system, and its movement trajectory was recorded and analyzed using ANY-maze software (Stoeling, USA). Each guinea pig repeated the training 5 times a day for 5 consecutive days. The swimming path of each guinea pig was observed and recorded. When its swimming trajectory was stable, the swimming trajectory was close to a straight line as the standard, and then the experiment was officially carried out. On the second day after the adaptive training, the guinea pigs were gavaged with an equal amount of physiological saline containing 0.5% sodium carboxymethyl cellulose. After 1 hour, the swimming trajectory of the guinea pig in a normal state was tested and recorded 5 times. The curvature of the guinea pig's swimming trajectory was calculated using the open source software Image J to obtain the average curvature of the swimming trajectory.

[0035] Rotation stimulation group (Rot.): The trained guinea pigs were subjected to 2 hours of rotation stimulation, and the stimulation parameters were the same as those of the conditioned taste aversion behavior induction experiment. Immediately after the stimulation, the guinea pigs were gavaged with an equal amount of physiological saline containing 0.5% sodium carboxymethylcellulose, and the swimming tracks of the guinea pigs were measured and recorded 5 times after 1 hour.

[0036] Eplerenone gavage group (Epl.): firstly, the above-mentioned rotation stimulation was carried out, and immediately after the stimulation, half of the normal dose of eplerenone (12.5 mg / kg) was gavaged to the guinea pigs. After 1 hour, the swimming trajectory of the guinea pigs was measured and recorded 5 times to observe the effect of eplerenone alone.

[0037] Isosorbide gavage group (Iso.): firstly, the above-mentioned rotation stimulation was carried out, and immediately after the stimulation, half the normal dose of 70% isosorbide (0.7 g / kg) was gavaged to the guinea pigs. After 1 hour, the swimming trajectory of the guinea pigs was measured and recorded 5 times to observe the effect of pure isosorbide.

[0038] The compound composition gavage group after rotation stimulation (Epl.+Iso.): The rotation stimulation under the same conditions as above was first performed, and immediately after the stimulation, the guinea pigs were gavaged with a compound composition of half the normal dose of eplerenone (12.5 mg / kg) and half the normal dose of 70% isosorbide (0.7 g / kg). After 1 hour, the swimming trajectory of the guinea pigs was measured and recorded 5 times, and compared with the performance of the control group and the rotation stimulation group to determine the anti-motion sickness effect of the compound composition of eplerenone and isosorbide. The results of each experimental group were statistically processed by variance analysis, and the Duncan test was used for pairwise comparison.

[0039] See also Figure 2Compared with the control group (Con.), the swimming path of the guinea pigs in the rotation stimulation group (Veh.) was curved after rotation, and the curvature of the swimming track increased significantly (P<0.01), indicating vestibular dysfunction. After rotation stimulation, the curvature of the swimming track of guinea pigs that were gavaged with eplerenone (12.5mg / kg, Epl.) or isosorbide (0.7g / kg, Iso.) alone decreased after 1 hour of administration, but there was no significant difference compared with the simple rotation stimulation group (Veh.) (P>0.05), indicating that the normal half-dose of eplerenone or isosorbide had no obvious inhibitory effect on motion sickness. However, after the combined use of half-dose eplerenone and isosorbide, the increase in the curvature of the swimming track induced by rotation stimulation was significantly inhibited (P<0.01, Epl.+Iso.), indicating that the compound of eplerenone and isosorbide inhibited the vestibular dysfunction of guinea pigs induced by rotation stimulation, that is, inhibited motion sickness.

[0040] The isosorbide in this application has no specific target except for the dehydrating effect, and it is found that it has a certain preventive and therapeutic effect on motion sickness. At the same time, this application finds that eplerenone, a second-generation mineralocorticoid receptor antagonist, also has a certain preventive and therapeutic effect on motion sickness. This application uses half of the original effective dose, and exerts a synergistic effect from different links to achieve a good effect of preventing and treating motion sickness, while reducing or alleviating the side effects of the original drugs. It can be used when motion sickness has already occurred, and it can also be used before taking a means of transportation. When motion sickness occurs, because the patient has nausea and vomiting, it affects the administration, and it can be used through the intravenous route.

[0041] The above descriptions are merely embodiments of the present application and are not intended to limit the patent scope of the present application. Any equivalent structure or equivalent process transformation made using the contents of the present application specification and drawings, or directly or indirectly applied in other related technical fields, are also included in the patent protection scope of the present application.

Claims

1. Use of a compound composition of eplerenone and isosorbide in the preparation of a product for treating or preventing motion sickness.

2. A product for treating or preventing motion sickness, characterized in that: The invention relates to a compound composition comprising eplerenone and isosorbide.

3. A product for treating or preventing motion sickness according to claim 2, characterized in that: The product produces an anti-motion sickness effect when used when or before motion sickness occurs.

4. A product for treating or preventing motion sickness according to claim 2, characterized in that: The product is in the form of an infusion or an oral dosage form.

5. A method for verifying that a compound composition of eplerenone and isosorbide inhibits motion sickness, characterized in that: The following steps are involved: S1. Obtain the drinking amount and swimming trajectory of 0.15% sodium saccharin solution of normal guinea pigs; S2. Obtain the drinking amount of 0.15% saccharin sodium solution of guinea pigs with motion sickness, the drinking amount of 0.15% saccharin sodium solution of guinea pigs gavaged with half the normal dose of eplerenone, the drinking amount of 0.15% saccharin sodium solution of guinea pigs gavaged with half the normal dose of 70% isosorbide, and the drinking amount of 0.15% saccharin sodium solution of guinea pigs gavaged with a compound composition of half the normal dose of eplerenone and half the normal dose of 70% isosorbide, and compare it with the drinking amount of 0.15% saccharin sodium solution of normal guinea pigs; S3. Obtain the swimming trajectories of guinea pigs with motion sickness, the swimming trajectories of guinea pigs gavaged with half the normal dose of eplerenone, the swimming trajectories of guinea pigs gavaged with half the normal dose of 70% isosorbide, and the swimming trajectories of guinea pigs gavaged with a combination of half the normal dose of eplerenone and half the normal dose of 70% isosorbide, and compare them with the swimming trajectories of normal guinea pigs.